Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Hercules Capital, Inc.

Founders Manuel A. Henriquez Roy Y. Liu Scott Harvey

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 255
Average round size
info
The average size of a deal this fund participated in
$38M
Portfolio companies 224
Rounds per year 12.14
Lead investments 76
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 140
Key employees 5
Stages of investment
Debt

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Software
Summary

In 2003 was created Hercules Capital, Inc., which is appeared as VC. The main department of described VC is located in the Palo Alto. The company was established in North America in United States.

The current fund was established by Manuel A. Henriquez, Scott Harvey. Besides them, we counted 5 critical employees of this fund in our database.

The higher amount of exits for fund were in 2010. The important activity for fund was in 2014. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Hercules Capital, Inc. performs on 24 percentage points more the average number of lead investments. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 7-12 deals per year.

Among the most successful fund investment fields, there are Medical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Anacor Pharmaceutical, Machine Zone, Zayo. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Hercules Capital, Inc., startups are often financed by VantagePoint Capital Partners, OrbiMed, InterWest Partners. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Venrock, Kleiner Perkins. In the next rounds fund is usually obtained by Venrock, Steamboat Ventures, General Motors Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Hercules Capital, Inc.:
Typical Co-investors
Hercules Capital, Inc. is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Hercules Capital, Inc.:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Benxi Steel Benxi, China, Liaoning
Clearvision Ventures California, Menlo Park, United States
Eterna Capital England, London, United Kingdom
Exnetwork Capital -
Gabriel Investments Pennsylvania, Philadelphia, United States
GuarantCo -
Hainan Huantai Equity Investment Fund Management China, Hainan, Hainan Province
Jennison Associates New York, New York, United States
Long Pinxi Capital -
LW Investment Management -
Meritage Funds Colorado, Denver, United States
Novelion Therapeutics British Columbia, Canada, Vancouver
Park House Ventures Cornwall, Truro, United Kingdom
Shalamuka Capital Gauteng, NA - South Africa, South Africa
Suzhou International Development Venture Capital China, Jiangsu, Suzhou
TAG Capital Arizona, Fountain Hills, United States
TrueBridge Capital Partners Chapel Hill, North Carolina, United States
Wutongshu Capital -
Zimi Fund China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Semperis

Cyber Security
Identity Management
Information Technology
$125M20 Jun 2024 New York, New York, United States

NorthSea Therapeutics

Biotechnology
Health Care
Therapeutics
$80M17 Dec 2021 The Netherlands, North Holland, Netherlands

CloudPay

Cloud Computing
Information Technology
Payments
SaaS
Software
$25M03 May 2018 Test Valley, England, United Kingdom

SparkPost

Analytics
Business Information Systems
Cloud Infrastructure
Email
Email Marketing
Messaging
Software
$27M18 Feb 2015 Columbia, Maryland, United States

Gamma Medica

Biotechnology
Health Care
Pharmaceutical
$5M22 Oct 2014 New Hampshire, United States

CapLinked

Collaboration
Enterprise Software
Finance
FinTech
Software
$2M29 Nov 2012 California, United States

E-Band Communications

Manufacturing
Telecommunications
Wireless
27 May 2009 San Diego, California, United States

E-Band Communications

Manufacturing
Telecommunications
Wireless
$10M11 Dec 2007 San Diego, California, United States

Elixir Pharmaceuticals

Biotechnology
Diabetes
Pharmaceutical
$31M27 Nov 2006 Cambridge, Massachusetts, United States
News
HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital

– HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m.
– The company closed on a $30m debt facility with Hercules Capital, Inc. (NYSE: HTGC).
– The Series B round included new investors Huizenga Capital Management, Monashee Investment Management, funds managed by Tekla Capital Management LLC, Hercules Capital, Mount Sinai Innovation Partners and other undisclosed investors.
– Returning investors, including ARCH Venture Partners, Magnetic Ventures, Bristol Myers Squibb, Trinitas Capital, and others from the Series A syndicate also participated in the round.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Hercules Capital, Inc.?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 255
Average round size 38M
Rounds per year 12.14
Peak activity year 2007
Lead investments 76
Follow on index 0.11
Exits 140
Group Appearance index 0.29

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Semperis

Cyber Security
Identity Management
Information Technology
$125M20 Jun 2024 New York, New York, United States

NorthSea Therapeutics

Biotechnology
Health Care
Therapeutics
$80M17 Dec 2021 The Netherlands, North Holland, Netherlands

CloudPay

Cloud Computing
Information Technology
Payments
SaaS
Software
$25M03 May 2018 Test Valley, England, United Kingdom

SparkPost

Analytics
Business Information Systems
Cloud Infrastructure
Email
Email Marketing
Messaging
Software
$27M18 Feb 2015 Columbia, Maryland, United States

Gamma Medica

Biotechnology
Health Care
Pharmaceutical
$5M22 Oct 2014 New Hampshire, United States

CapLinked

Collaboration
Enterprise Software
Finance
FinTech
Software
$2M29 Nov 2012 California, United States

E-Band Communications

Manufacturing
Telecommunications
Wireless
27 May 2009 San Diego, California, United States

E-Band Communications

Manufacturing
Telecommunications
Wireless
$10M11 Dec 2007 San Diego, California, United States

Elixir Pharmaceuticals

Biotechnology
Diabetes
Pharmaceutical
$31M27 Nov 2006 Cambridge, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: